AbbVie 8-K
NegativeEarningsGuidance loweredImpairment / charge
Acquired in-process R&D and milestone expenses lower Q1 and FY2026 adjusted EPS guidance.
Filed 2026-04-03 16:05 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Preliminary Q1 2026 expense disclosure and updated adjusted EPS guidance. AbbVie expects $744M of acquired in-process research and development and milestone expense, reducing both GAAP and adjusted diluted EPS by $0.41. The quarter’s results are not final and remain subject to closing procedures.
Key Figures
- Q1 2026 acquired in-process research and development and milestone expense: $744M pre-tax; unfavorable $0.41 impact on both GAAP and adjusted diluted EPS.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted diluted EPS | Q1 2026 | $2.56-$2.60 | $2.97-$3.01 | Lowered |
| Adjusted diluted EPS | FY2026 | $13.96-$14.16 | $14.37-$14.57 | Lowered |
The updated ranges include the Q1 expense; adjusted EPS guidance excludes any acquired in-process research and development and milestone expense beyond Q1 because it cannot be reliably forecast.
Investor Takeaways
- Watch finalized Q1 results, which could differ from the preliminary disclosure.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3